Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) dropped 4.6% on Monday . The stock traded as low as GBX 180 and last traded at GBX 187. Approximately 6,721 shares changed hands during mid-day trading, a decline of 38% from the average daily volume of 10,887 shares. The stock had previously closed at GBX 196.
Faron Pharmaceuticals Oy Stock Down 4.6%
The firm has a 50-day moving average of GBX 184.03 and a 200 day moving average of GBX 192.60. The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The stock has a market capitalization of £213.97 million, a price-to-earnings ratio of -6.93 and a beta of 0.36.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Stories
- Five stocks we like better than Faron Pharmaceuticals Oy
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Gold Breakout ALERT
- Trump’s Hand-Written Letter Will Shock his Haters
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
